Watchlist

•

	DJIA F	24,309	89	0.37%
	S&P F	2,726.75	7.25	0.27%
	NASDAQ F	7,082.25	21.75	0.31%
	Gold	1,253.70	2.70	0.22%
	Silver	16.22	0.061	0.38%
	Crude Oil	73.53	0.08	0.11%

S&P 500 Movers(%)

Latest NewsAll Times Eastern

9:05a
Updated How the opioid epidemic is exacerbating a U.S. labor-market shortage
9:00a
An investing playbook for 2018’s 2nd half — with how U.S. stocks stand apart
8:57a
Updated How blood-testing startups are pitching themselves after the Theranos scandal
8:56a
Updated Meet the one patient who will get access to this experimental ALS therapy before it’s approved
8:56a
Updated Amazon acquisition of online pharmacy startup PillPack sends health-care stocks into a nose dive
8:55a
Gold improves but still on track for 6% quarterly retreat
8:53a
Updated Mortgage rates slump as trade fears weigh on a housing market that’s running dry
8:51a
Trump reportedly wants U.S. to quit the WTO | Kudlow jawbones the Fed
8:51a
Synlogic started at outperform with $18 stock price target at Oppenheimer
8:51a
Alpine Immune Sciences started at outperform with $13 stock price target at Oppenheimer

|

ALPN U.S.: Nasdaq

Alpine Immune Sciences Inc.

Watchlist CreateALPNAlert

ALPNUSClosedBack To Top

Last Updated: Jun 28, 2018 3:59 p.m. EDT Delayed quote

^$ 7.22

-0.38 -5.00%

Previous Close
$7.60

Advanced Charting

$
%
Vol

Advanced Charting

19.09% vs Avg.

Volume: 3.7K 65 Day Avg. - 19.3K

Open: 7.80

Close: 7.22

7.22 Day Low/High 7.80

Day Range

6.85 52 Week Low/High 12.87

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Create Account … or Log In

	Symbol Company	Price Chg/Chg %

(Go to Your Watchlist)

No Items in Watchlist

There are currently no items in this Watchlist.

Add Tickers

No Saved Watchlists

Create a list of the investments you want to track.

Create Watchlist …or try this starter list

Uh oh

Something went wrong while loading Watchlist.

Go to Watchlist

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Open $7.80
Day Range 7.22 - 7.80
52 Week Range 6.85 - 12.87
Market Cap $100.23M
Shares Outstanding 13.88M
Public Float 7.77M
Beta 0.58
Rev. per Employee $15.03K
P/E Ratio n/a
EPS $-1.47
Yield n/a
Dividend n/a
Ex-Dividend Date n/a
Short Interest 28.35K 06/15/18
% of Float Shorted 0.36%
Average Volume 19.29K

5 Day	-6.96%
1 Month	-19.24%
3 Month	-9.75%
YTD	-35.54%
1 Year	-25.10%

MarketWatch
Other Dow Jones

Alpine Immune Sciences started at outperform with $13 stock price target at Oppenheimer

Alpine Immune Sciences started at outperform with $13 stock price target at Oppenheimer

Jun. 29, 2018 at 8:51 a.m. ET
by Tomi Kilgore

Alpine Immune Sciences initiated at outperform at Wedbush

Alpine Immune Sciences initiated at outperform at Wedbush

May. 18, 2018 at 7:58 a.m. ET
by Ciara Linnane

Alpine Immune Sciences upgraded to buy from hold at Stifel Nicolaus

Sep. 22, 2017 at 8:48 a.m. ET
by Tomi Kilgore

Alpine Immune Services started at buy with $17 stock price target at Ladenburg Thalmann

Jul. 27, 2017 at 8:58 a.m. ET
by Tomi Kilgore

Nivalis to lay off CEO and 80% of staff as part of restructuring

Jan. 12, 2017 at 4:30 p.m. ET
by Sue Chang

Nivalis Therapeutics downgraded to market perform from outperform at Raymond James

Nov. 29, 2016 at 8:19 a.m. ET
by Tomi Kilgore

Nivalis' stock loses half its value after failed trial prompts analyst downgrades

Nov. 29, 2016 at 8:16 a.m. ET
by Tomi Kilgore

Nivalis Therapeutics' stock plunges 54% premarket after disappointing trial results late Monday

Nov. 29, 2016 at 7:58 a.m. ET
by Tomi Kilgore

Nivalis Therapeutics downgraded to hold from buy at Stifel Nicolaus

Nov. 29, 2016 at 7:14 a.m. ET
by Tomi Kilgore

Nivalis Therapeutics downgraded to neutral from outperform at RW Baird

Nov. 29, 2016 at 7:12 a.m. ET
by Tomi Kilgore

Nivalis Therapeutics plummet as cystic fibrosis drug study fails

Nov. 28, 2016 at 4:41 p.m. ET
by Wallace Witkowski

Nivalis Therapeutics started at outperform with $20 stock price target at Raymond James

Sep. 13, 2016 at 8:53 a.m. ET
by Tomi Kilgore

Nivalis Therapeutics started at buy, $23 stock price target at Stifel Nicolaus

Jul. 13, 2015 at 7:30 a.m. ET
by Tomi Kilgore

By This Measure, U.S. Stocks Only Now Ready to Push Past Their 1998 Top

By This Measure, U.S. Stocks Only Now Ready to Push Past Their 1998 Top

Nov. 29, 2016 at 9:16 a.m. ET
on The Wall Street Journal

Semi Equipment: Credit Suisse Now "Tactically Bullish"

Jul. 6, 2009 at 1:23 p.m. ET
on Barron's Online

Novellus Re-affirms Q2 Forecast, Sees Bookings Improve

May. 28, 2009 at 5:04 p.m. ET
on Barron's Online

Semi Equipment: Stifel Upgrades TER, PLAB, NVLS, CYMI

May. 18, 2009 at 1:04 p.m. ET
on Barron's Online

Novellus: Cheap On Normalized Earnings, Merrill Says

May. 14, 2009 at 10:32 a.m. ET
on Barron's Online

Lam Research Q1 In Line; Sees Q2 Revs Modestly Higher

Apr. 22, 2009 at 11:07 p.m. ET
on Barron's Online

Novellus Q1 EPS Beats; Sees Q2 Sales Above Estimates

Apr. 22, 2009 at 5:54 p.m. ET
on Barron's Online

Novellus Could Be Takeover Target, Oppenheimer Says

Mar. 27, 2009 at 11:44 a.m. ET
on Barron's Online

Novellus Repeats Q1 View; Sees Pick Up In Spares Orders

Mar. 11, 2009 at 4:55 p.m. ET
on Barron's Online

What’s Up With AMAT And The Equipment Stocks?

Feb. 25, 2009 at 3:44 p.m. ET
on Barron's Online

Semi Equip Book-To-Bill Hits 0.1 As Orders Evaporate

Feb. 25, 2009 at 2:10 p.m. ET
on Barron's Online

Novellus Revs Drop 48%; Sees Q1 Down At Least 65%

Feb. 4, 2009 at 9:20 p.m. ET
on Barron's Online

Intevac Q4 Sales Above Estimates, EPS Falls Short

Feb. 3, 2009 at 5:45 p.m. ET
on Barron's Online

Applied Materials Cuts Q1 Outlook, Warns of Shutdowns

Feb. 2, 2009 at 11:59 a.m. ET
on Barron's Online

Semi Cap Equipment: RBC Cuts Ests On AMAT, NVLS, KLAC; Sees 45% Drop In Spending In 2009

Jan. 21, 2009 at 11:24 a.m. ET
on Barron's Online

Semi Equipment Bookings Fall Sharply In December

Jan. 21, 2009 at 1:25 a.m. ET
on Barron's Online

Semi Cap Equipment: Bracing For A Miserable 2009

Jan. 5, 2009 at 11:00 a.m. ET
on Barron's Online

Caris Sees No Rebound in Sight For Semi Cap Ex

Dec. 29, 2008 at 10:25 a.m. ET
on Barron's Online

Novellus Says Q4 Results Coming In Below Guidance

Dec. 9, 2008 at 9:47 a.m. ET
on Barron's Online

Novellus Cuts Guidance As Demand Plummets

Nov. 20, 2008 at 5:29 p.m. ET
on Barron's Online

Other News
Press Releases

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

Jun. 16, 2018 at 9:00 a.m. ET
on Seeking Alpha

Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

Jun. 7, 2018 at 5:22 p.m. ET
on Seeking Alpha

Integrated BioSci Investing Research: Portfolio Management And Investment Strategy

Integrated BioSci Investing Research: Portfolio Management And Investment Strategy

Jun. 7, 2018 at 6:50 a.m. ET
on Seeking Alpha

Rounds Report: Alpine Rallies; Eleven BioTherapeutics Becomes Sesen Bio

Rounds Report: Alpine Rallies; Eleven BioTherapeutics Becomes Sesen Bio

May. 20, 2018 at 9:00 p.m. ET
on Seeking Alpha

Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation

Alpine Is A Buy Ahead Of Clinical Trials, Wedbush Says In Positive Initiation

May. 18, 2018 at 2:01 p.m. ET
on benzinga.com

Premarket analyst action - healthcare

Premarket analyst action - healthcare

May. 18, 2018 at 8:57 a.m. ET
on Seeking Alpha

Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

May. 11, 2018 at 2:25 a.m. ET
on Seeking Alpha

Alpine: Explicating The Upcoming Catalysts Powering Robust Potential For This Stock

Alpine: Explicating The Upcoming Catalysts Powering Robust Potential For This Stock

May. 10, 2018 at 3:07 a.m. ET
on Seeking Alpha

Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators

Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators

Apr. 13, 2018 at 12:14 a.m. ET
on Seeking Alpha

An Integrated BioSci Report On Alpine Immune Sciences: A Stellar Next-Generation Immunotherapy Innovator

An Integrated BioSci Report On Alpine Immune Sciences: A Stellar Next-Generation Immunotherapy Innovator

Apr. 1, 2018 at 3:18 a.m. ET
on Seeking Alpha

10-K: ALPINE IMMUNE SCIENCES, INC.

Mar. 28, 2018 at 8:30 a.m. ET
on Edgar Online - (EDG = 10Q, 10K)

4th-Quarter 2017 Portfolio Review And Price Increase For Integrated BioScI Investing

Jan. 11, 2018 at 3:31 a.m. ET
on Seeking Alpha

What The Cell Design Labs Acquisition Means For Gilead?

Dec. 18, 2017 at 11:53 a.m. ET
on Seeking Alpha

How To Make Money With Gilead?

Nov. 16, 2017 at 5:32 a.m. ET
on Seeking Alpha

10-Q: ALPINE IMMUNE SCIENCES, INC.

Nov. 14, 2017 at 6:17 a.m. ET
on Edgar Online - (EDG = 10Q, 10K)

Integrated BioSci Research On Gilead Sciences: Hitting The Next Growth Spurt With CAR-TCR And TIP-VIgD

Nov. 12, 2017 at 2:48 a.m. ET
on Seeking Alpha

Alpine extends research term under Kite Pharma deal

Oct. 23, 2017 at 12:37 p.m. ET
on Seeking Alpha

Biotech: The Big Payoff

Sep. 23, 2017 at 7:30 a.m. ET
on Seeking Alpha

Premarket analyst action - healthcare

Sep. 22, 2017 at 7:58 a.m. ET
on Seeking Alpha

How To Value Biotech Firms?

Sep. 5, 2017 at 2:11 p.m. ET
on Seeking Alpha

Alpine Immune Sciences to Present at Jefferies 2018 Global Healthcare Conference

Alpine Immune Sciences to Present at Jefferies 2018 Global Healthcare Conference

May. 22, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2018 Financial Results

May. 14, 2018 at 4:00 p.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors

Alpine Immune Sciences Appoints Life Sciences Executive Chris Peetz to its Board of Directors

Apr. 24, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer Model

Alpine Immune Sciences Announces Preclinical Data Demonstrating ALPN-202 Eliminates Tumors and Creates Persistent Tumor Resistance in a Murine Cancer Model

Apr. 17, 2018 at 2:00 p.m. ET
on BusinessWire - BZX

Blog Exposure - ImmunoCellular Therapeutics Reported Achievement of Next Key Milestone in Validating Stem-to-T-Cell Program

Blog Exposure - ImmunoCellular Therapeutics Reported Achievement of Next Key Milestone in Validating Stem-to-T-Cell Program

Apr. 16, 2018 at 7:51 a.m. ET
on ACCESSWIRE

Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2017 Financial Results

Mar. 28, 2018 at 7:43 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual Meeting

Mar. 14, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences to Present at Cowen 38th Annual Health Care Conference

Feb. 27, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease

Dec. 9, 2017 at 7:30 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells

Dec. 6, 2017 at 7:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting

Nov. 10, 2017 at 7:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation

Nov. 6, 2017 at 7:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences to Present at Two Upcoming Investor Conferences in November

Nov. 1, 2017 at 4:05 p.m. ET
on BusinessWire - BZX

Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs

Oct. 23, 2017 at 7:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Announces Upcoming Scientific Presentations

Oct. 16, 2017 at 7:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting

Sep. 20, 2017 at 8:01 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference

Sep. 13, 2017 at 4:05 p.m. ET
on BusinessWire - BZX

Corporate News Blog - Alpine Immune Sciences Goes Public on NASDAQ; Announces the Completion of an Immuno-Oncology Merger with Nivalis Therapeutics

Jul. 27, 2017 at 7:12 a.m. ET
on ACCESSWIRE

Nivalis Therapeutics Announces Results of Special Meeting of Stockholders

Jul. 20, 2017 at 6:00 a.m. ET
on BusinessWire - BZX

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded on July 24, 2017 and is headquartered in Seattle, WA. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 2 Full Ratings

Benzinga's Top Upgrades, Downgrades For September 22, 2017

Sep. 22, 2017 at 9:59 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For July 27, 2017

Jul. 27, 2017 at 8:57 a.m. ET
on Benzinga.com

Looking For Leftover Value in Nivalis Following Drug Trial Miss

Nov. 29, 2016 at 1:50 p.m. ET
on Benzinga.com